

# Novel Therapies for *EGFR* Exon 20 Insertions and *ALK*-Positive NSCLC

## Developments and Implications

WEDNESDAY, 30 MARCH 2022 | 18:15 – 19:45 CEST

CHANNEL: SOUTH HALL 2

 VIRTUAL EVENT

### CHAIR



**Martin Reck, MD, PhD**  
Head of Thoracic Oncology  
Hospital Großhansdorf  
Großhansdorf, Germany

### FACULTY



**Maurice Pérol, MD**  
Medical Director  
Thoracic Oncology Program  
Léon Bérard Cancer Center  
Lyon, France



**Sanjay Popat, PhD, FRCP**  
Professor of Thoracic Oncology  
The Institute of Cancer Research  
Consultant Medical Oncologist  
Royal Marsden Hospital  
London, United Kingdom

### AGENDA

**18:15**

**Welcome and Introduction**

Martin Reck, MD, PhD

**18:20**

***Precision Medicine in NSCLC: From Biomarker Testing to Therapy Selection***

Martin Reck, MD, PhD

**18:35**

***Emerging Therapies for Advanced NSCLC With EGFR Exon 20 Insertion Mutations: Developments and Implications***

Maurice Pérol, MD

**19:00**

***Frontline Treatment of ALK-Positive NSCLC: Therapy Considerations and Selection***

Sanjay Popat, PhD, FRCP

**19:25**

**Q&A**

All Faculty

**19:43**

**Concluding Remarks**

Martin Reck, MD, PhD